Also, YAP1 regulates anaplastic lymphoma kinase (ALK) by inhibiting the anti-apoptotic factors MCL1 apoptosis regulator and Bcl-xL (B cell leukemia/lymphoma), which has clinical significance for molecular targeted therapy in non-small cell lung cancer with ALK-positive mutations. This evidence concerns the gene ALK and lymphoma.